1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

Gottlieb Leaves FDA With Final Thought On What To Do About Cosmetics

 
• By Ryan Nelson

Addressing for the last time the House Appropriations subcommittee with FDA oversight, Commissioner Scott Gottlieb shared his vision for sharpening cosmetics oversight in the absence of significant new resources.

FDA entrance sign 2016

FDA’s 23rd Commissioner Scott Gottlieb has returned to the American Enterprise Institute, a Washington-based public policy think tank, after two years at FDA’s helm.

As a resident fellow at AEI, a position he held previously at the nonprofit beginning in 2003, Gottlieb “continues his...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

MoCRA Implementation Delay Creates More Legal Exposure For Stakeholders – Attorney

 
• By Eileen Francis

The delay in implementation of MoCRA is seen by many companies as a temporary reprieve, but it does create more legal uncertainty, says attorney Marissa Alkhazov of law firm Buchalter.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

Animal Studies Would Not Provide ‘Meaningful Insights’ Into UV Filter Safety - Study

 
• By Lauren Nardella

A new study on the safety of sunscreen filters relies on an alternative assessment methodology and concludes that six sunscreen UV filters are unlikely to be carcinogenic.

EU’s Small, Medium Beauty Industry Pushing For Clarity In Revised CPR

French SME association COSMED will push the European Commission for a “clear checklist” and criteria on how substances in the Cosmetic Products Regulation are assessed by Member States, as well as more clarity on the exemption process and timelines.

More from Policy & Regulation

House Bill Aims to ‘Modernize’ US FDA’s Review Process For Sunscreens

 
• By Eileen Francis

Four co-chairs of the House of Representatives’ Skin Cancer Caucus have introduced the Safe Sunscreen Standards Act to direct FDA to establish clearer, ‘more flexible’ standards for evaluating sunscreen ingredients.

Beauty Industry: Counter Impact Of State Legislation By Connecting With Lawmakers – IBA

 
• By Eileen Francis

Beauty stakeholders will undoubtedly feel the impact of new state laws targeting cosmetic ingredients and packaging and should therefore open lines of communication with state lawmakers.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.